Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC-1119 in mCRPC patients post-abiraterone and docetaxel
NCT03851640Phase 3Recruiting
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Apr 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deutenzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hinova Pharmaceuticals Inc.. Started Apr 2019; status: recruiting.
02
Drugs
deutenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03851640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851640.